Leading contract development and manufacturing organization (CDMO), Stelis BioSource™, a division of Stelis Biopharma Pvt. Ltd., has started the next phase of its continued investment program after having already invested well over $100m into its facilities in Bangalore, India.
17 November, 2020
Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431; Inhibitors discovered at Domainex via virtual and fragment screening
11 November, 2020
RSM webinar: Tuesday 17 November, 10.00am to 4.15pmSession introducing new guidance: 1.00pm
11 November, 2020
Solna, Sweden, November 10, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today announced the initiation of its 52-week trial investigating the novel bispecific IL-17A inhibitor ABY-035 in patients with psoriatic arthritis (PsA).
10 November, 2020
The collaboration will see the integration of Optibrium’s StarDrop software as a central component of MSD’s global drug discovery infrastructure
10 November, 2020
Talking Medicines, the world’s first social intelligence company for the pharmaceutical industry, has received a significant boost with a £1.1 million funding deal to scale up its AI-based data technology platform for measuring patient sentiment.
06 November, 2020
High throughput research grade material to GMP production batches
06 November, 2020
London, November 4th, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had received CTA Acceptance from the Medicines Healthcare products Regulatory Agency (MHRA) to carry out a Phase II clinical Study for its NM-01 product.
05 November, 2020
Inaugural 2020 Testa Challenge held in Sweden for bioprocessing innovators
05 November, 2020
The national programme, to develop and progress start-up oncology projects, is being launched by Bruntwood SciTech at Alderley Park - the UK’s largest single site life science campus - with funding from Innovate UK and Cancer Research UK. It comprises a unique collaboration of global pharmaceutical and healthcare companies, research institutions and public bodies will identify oncology innovations and leverage their combined insight and expertise to nurture them into investment ready start-ups. Its goal is to bring forward viable oncology projects much more quickly in order to significantly increase their likelihood of commercial success. The Oncology Development Programme aims to find and develop innovations that improve the diagnosis and treatment of cancer
02 November, 2020
The topic of this month’s newsletter from Drug Discovery Today is “Medicinal Chemistry and Disease Models”.
02 November, 2020